These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 39206905)
1. METTL14-Mediated m6A Modification of Gu X; Song Y; Liu X; Cheng Z; Min J; Zhang Y Front Biosci (Landmark Ed); 2024 Aug; 29(8):298. PubMed ID: 39206905 [TBL] [Abstract][Full Text] [Related]
2. METTL14 promotes chondrocyte ferroptosis in osteoarthritis via m6A modification of GPX4. Liu D; Ren L; Liu J Int J Rheum Dis; 2024 Aug; 27(8):e15297. PubMed ID: 39175261 [TBL] [Abstract][Full Text] [Related]
3. METTL14 inhibits Aβ1-42-induced neuronal injury through regulating the stability of CBLN4 mRNA in Alzheimer's disease. Mu B; Jing J; Li R; Li C J Bioenerg Biomembr; 2024 Oct; 56(5):495-504. PubMed ID: 39235700 [TBL] [Abstract][Full Text] [Related]
4. METTL14 Regulates the m6A Modification of TRAF6 to Suppress Mitochondrial Dysfunction and Ferroptosis in Dopaminergic Neurons via the cGAS-STING Pathway. Shao L; Hu F; Xu R; Nie H; Zhang H; Zhang P Curr Mol Med; 2024; 24(12):1518-1528. PubMed ID: 37881068 [TBL] [Abstract][Full Text] [Related]
5. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946 [TBL] [Abstract][Full Text] [Related]
6. METTL14 plays an oncogenic role in NSCLC by modulating ferroptosis and the m6A modification of GPX4. Lou Y; Huang K; Xu B; Chen X Arch Physiol Biochem; 2024 Dec; 130(6):962-973. PubMed ID: 38993012 [TBL] [Abstract][Full Text] [Related]
7. METTL14-mediated N6-methyladenosine modification induces the ferroptosis of hypoxia/reoxygenation-induced cardiomyocytes. Zhao C; Li J J Cardiothorac Surg; 2024 Apr; 19(1):265. PubMed ID: 38664788 [TBL] [Abstract][Full Text] [Related]
8. Propofol attenuates prostate cancer progression by upregulating TRHDE-AS1 expression, and METTL14 could mediate its m6A modification. Chen Z; Li Q; Li Z; Hu G Clin Exp Pharmacol Physiol; 2024 Nov; 51(11):e13924. PubMed ID: 39322401 [TBL] [Abstract][Full Text] [Related]
9. KDM1A-mediated upregulation of METTL3 ameliorates Alzheimer's disease via enhancing autophagic clearance of p-Tau through m6A-dependent regulation of STUB1. Tang Z; Cao J; Yao J; Fan X; Zhao J; Zhao M; Duan Q; Han B; Duan S Free Radic Biol Med; 2023 Feb; 195():343-358. PubMed ID: 36587923 [TBL] [Abstract][Full Text] [Related]
10. METTL14 decreases FTH1 mRNA stability via m6A methylation to promote sorafenib-induced ferroptosis of cervical cancer. Li L; Zeng J; He S; Yang Y; Wang C Cancer Biol Ther; 2024 Dec; 25(1):2349429. PubMed ID: 38738555 [TBL] [Abstract][Full Text] [Related]
11. N6-methyladenosine methyltransferase plays a role in hypoxic preconditioning partially through the interaction with lncRNA H19. Su Y; Xu R; Zhang R; Qu Y; Zuo W; Ji Z; Geng H; Pan M; Ma G Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1306-1315. PubMed ID: 33197240 [TBL] [Abstract][Full Text] [Related]
12. Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1. Liu T; Wang H; Fu Z; Wang Z; Wang J; Gan X; Wang A; Wang L Cancer Sci; 2022 Feb; 113(2):446-458. PubMed ID: 34813676 [TBL] [Abstract][Full Text] [Related]
13. Eriodictyol ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via vitamin D receptor-mediated Nrf2 activation. Li L; Li WJ; Zheng XR; Liu QL; Du Q; Lai YJ; Liu SQ Mol Med; 2022 Jan; 28(1):11. PubMed ID: 35093024 [TBL] [Abstract][Full Text] [Related]
14. Methyltransferase like-14 suppresses growth and metastasis of non-small-cell lung cancer by decreasing LINC02747. Wang J; Wang S; Yang H; Wang R; Shi K; Liu Y; Dou L; Yu H Cancer Sci; 2024 Sep; 115(9):2931-2946. PubMed ID: 38888105 [TBL] [Abstract][Full Text] [Related]
15. METTL14-mediated lncRNA-FAS-AS1 promotes osteoarthritis progression by up-regulating ADAM8. Zhang Z; Mao H; Li F; Wang D; Liu Y Int J Rheum Dis; 2024 Sep; 27(9):e15323. PubMed ID: 39221886 [TBL] [Abstract][Full Text] [Related]
16. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762 [TBL] [Abstract][Full Text] [Related]
17. METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA. Meng L; Lin H; Huang X; Weng J; Peng F; Wu S Cell Death Dis; 2022 Jan; 13(1):38. PubMed ID: 35013106 [TBL] [Abstract][Full Text] [Related]
18. METTL14 represses osteoclast formation to ameliorate osteoporosis via enhancing GPX4 mRNA stability. Deng M; Luo J; Cao H; Li Y; Chen L; Liu G Environ Toxicol; 2023 Sep; 38(9):2057-2068. PubMed ID: 37195267 [TBL] [Abstract][Full Text] [Related]
19. METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion. Zhang BY; Han L; Tang YF; Zhang GX; Fan XL; Zhang JJ; Xue Q; Xu ZY Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):7015-7023. PubMed ID: 32633395 [TBL] [Abstract][Full Text] [Related]
20. WTAP-mediated N6-methyladenosine modification promotes the inflammation, mitochondrial damage and ferroptosis of kidney tubular epithelial cells in acute kidney injury by regulating LMNB1 expression and activating NF-κB and JAK2/STAT3 pathways. Huang F; Wang Y; Lv X; Huang C J Bioenerg Biomembr; 2024 Jun; 56(3):285-296. PubMed ID: 38517565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]